Alisertib (MNL8237), an investigational inhibitor of Aurora kinase A developed by Takeda Inc., currently being tested in several adult cancer clinical trials, binds to the catalytic domain of Aurora kinase A and causes an allosteric change in the protein structure. This evidence concerns the gene AURKA and cancer.